A Leader in Innate Immunity

About Us Cell

At IFM Therapeutics, we are transforming immunotherapy to improve the lives of patients with serious diseases. We focus on developing drugs that precisely target the innate immune system, the body’s first line of immunological response.

The majority of advances in immunotherapy have focused largely on targeting the adaptive immune system, which historically has been the best-characterized part of the immune system. While many of these approaches can work well, the benefit is seen only in a small number of diseases and over time, patients can lose response to these therapies. However, our understanding of the innate immune system has matured sufficiently, that we can now think about exploiting this biology to advance a new generation of medicines for inflammatory disorders and cancer. IFM Therapeutics has brought together the key academic thought leaders and advisors in this field, along with an exceptionally talented group of pharmaceutical scientists and executives, to make this goal a reality.

By focusing on innate immunity, IFM Therapeutics is looking to solve the limitations faced by current immunotherapies by dramatically increasing the number of patients that benefit from treatment and extending the duration of therapeutic response.

Building on
Expertise and Innovation

Our company was founded by an international group of preeminent scientists and physicians who have spent decades unraveling the complexities of innate immunity and the role it plays in health and disease. We have assembled an unparalleled team committed to innovation and scientific rigor to rapidly develop a novel pipeline of drug candidates.

Meet Our Leadership Team

We have assembled a tailor-made team with proven expertise in developing transformative medicines that will further our goal of bringing the most promising immunotherapies to patients with inflammatory diseases and cancer.

Leadership
Board
Scientific Founders
Clinical Advisory Board
Scientific Advisory Board

Our Investors

IFM Therapeutics was founded in 2015 as part of a seed program by Atlas Venture. In June 2016, we announced a $27 million series A financing led by Atlas Venture and Abingworth, with participation from Novartis.